| 000 | 01903 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517114712.0 | ||
| 264 | 0 | _c20171207 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1573-7217 | ||
| 024 | 7 |
_a10.1007/s10549-016-3969-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHainsworth, John D | |
| 245 | 0 | 0 |
_aUse of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. _h[electronic resource] |
| 260 |
_bBreast cancer research and treatment _c11 2016 |
||
| 300 |
_a41-49 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoassay _xmethods |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNeoplastic Cells, Circulating _xmetabolism |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMurphy, Patrick B | |
| 700 | 1 | _aAlemar, Jose R | |
| 700 | 1 | _aDaniel, Brooke R | |
| 700 | 1 | _aYoung, Robyn R | |
| 700 | 1 | _aYardley, Denise A | |
| 773 | 0 |
_tBreast cancer research and treatment _gvol. 160 _gno. 1 _gp. 41-49 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10549-016-3969-7 _zAvailable from publisher's website |
| 999 |
_c26422292 _d26422292 |
||